Multi-faceted line of reagents for cancer research includes reagents and tests for the analysis of different aspects of carcinogenesis, and several new antibodies in a drug resistance product line. Three of these antibodies (MAB4155, MAB4145, and MAB4146) recognize internal or external epitopes of Bcrp, a new transmembrane protein pump expressed in a variety of drug resistant tumors and normal stem cells. Another important addition to Chemicon's tumor angiogenesis product line was the recent exclusive licensing of the Hypoxyprobe technology from the University of North Carolina. Hypoxyprobe kits (currently available in 100 mg and 1000 mg formats, HP1-100 and HP1-1000) allow for simple detection of hypoxia gradients in normal and tumor tissues. Each kit consists of two principal components: a hypoxia marker, pimonidazole hydrochloride, that selectively binds to oxygen-starved cells, and a monoclonal antibody that recognizes reductively-activated pimonidazole adducts. Hypoxyprobe kits can be used to detect and quantify hypoxia gradients in tumor tissues and individual cells using flow cytometry, IHC, ELISA, fine needle aspiration, and other standard laboratory techniques.